High affinity small molecule C5a receptor modulators
    1.
    发明授权
    High affinity small molecule C5a receptor modulators 失效
    高亲和力小分子C5a受体调节剂

    公开(公告)号:US06723743B1

    公开(公告)日:2004-04-20

    申请号:US09672071

    申请日:2000-09-28

    IPC分类号: A61K31415

    摘要: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors, preferably human C5a receptors, Preferred compounds of the invention possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are; 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sub-lethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vitro effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at sub-nanomolar concentrations. Specifically exemplified representative compounds include, but are not limited to optionally substituted arylimidazoles, optionally substituted arylpyridyls, optionally substituted aryl-substituted cycloalkylimidazoles, optionally substituted arylpyrazoles, optionally substituted benzimidazoles, optionally substituted aryl-substituted tetrahydroisoquinolines, and optionally substituted biaryl carboxamides. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

    摘要翻译: 本发明涉及作为哺乳动物补体C5a受体调节剂的低分子量,非肽,非拟肽,有机分子,优选用作高亲和力C5a受体配体的调节剂,还涉及作为拮抗剂或反向激动剂的这些配体 的补体C5a受体,优选人C5a受体。本发明的优选化合物具有一个或多个,优选两个或更多个,三个或更多个,四个或更多个或全部以下性质: 1)结构上的多芳基(具有多个未稠合或稠合芳基),2)结构上的杂芳基,3)在体内可口服(使得亚致死或优选药学上可接受的口服剂量可提供 可检测的体外效应,例如C5a诱导的中性粒细胞减少的减少),4)由少于4个,优选少于3个,或少于2个或不存在的酰胺键组成,以及5)能够以纳摩尔浓度抑制白细胞趋化性, 优选亚纳摩尔浓度。 具体示例的代表性化合物包括但不限于任选取代的芳基咪唑,任选取代的芳基吡啶基,任选取代的芳基取代的环烷基咪唑,任选取代的芳基吡唑,任选取代的苯并咪唑,任选取代的芳基取代的四氢异喹啉和任选取代的双芳基甲酰胺。 本发明还涉及包含这些化合物的药物组合物。 它还涉及这些化合物在治疗各种炎性和免疫系统疾病中的应用。 此外,本发明涉及使用这些化合物作为C5a受体定位的探针。

    Multi port nozzle point injection system
    10.
    发明授权
    Multi port nozzle point injection system 有权
    多口喷嘴点喷射系统

    公开(公告)号:US09061296B2

    公开(公告)日:2015-06-23

    申请号:US13339591

    申请日:2011-12-29

    申请人: John Peterson

    发明人: John Peterson

    摘要: A multi port nozzle may be provided. The multi port nozzle may include a main inlet. In addition, the multi port nozzle may include a first chamber branching off from the main inlet. The first chamber may have a first port. Moreover, the multi port nozzle may include a second chamber branching off from the main inlet. The second chamber may be separated from the first chamber by a partition and may have a second port. The first chamber may include a first plurality of mixing elements and the second chamber may include a second plurality of mixing elements.

    摘要翻译: 可以提供多端口喷嘴。 多口喷嘴可以包括主入口。 此外,多端口喷嘴可以包括从主入口分支的第一室。 第一个舱可能有第一个港口。 此外,多口喷嘴可以包括从主入口分支的第二室。 第二室可以通过隔板与第一室隔开,并且可以具有第二端口。 第一腔室可以包括第一多个混合元件,并且第二腔室可以包括第二多个混合元件。